4-(1-isopropyl-2-(methoxymethyl)-1H-imidazol-5-yl)pyrimidin-2-amine | 893420-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(1-isopropyl-2-(methoxymethyl)-1H-imidazol-5-yl)pyrimidin-2-amine
• 英文别名: 4-[2-(methoxymethyl)-3-propan-2-ylimidazol-4-yl]pyrimidin-2-amine
• CAS: 893420-56-9
• 化学式: C₁₂H₁₇N₅O
• 分子量: 247.3
• InChiKey: QSAJNSFNVLDTQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.65
• 重原子数：
  18.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  78.85
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  4-(1-isopropyl-2-(methoxymethyl)-1H-imidazol-5-yl)pyrimidin-2-amine 、 N-甲基-4-溴苯甲酰胺 在 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(4-(1-isopropyl-2-(methoxymethyl)-1H-imidazol-5-yl)pyrimidin-2-ylamino)-N-methylbenzamide
  参考文献：
  名称：

  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was pro. led in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.075
• 作为产物：
  描述：

  5-(3-dimethylaminoprop-2-en-1-oyl)-1-isopropyl-2-methoxymethylimidazole 、 碳酸胍 以 正丁醇 为溶剂， 生成 4-(1-isopropyl-2-(methoxymethyl)-1H-imidazol-5-yl)pyrimidin-2-amine
  参考文献：
  名称：

  Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

  摘要：

  The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was pro. led in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.075